Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2013

View Archived Issues

Aftins, a chemical model of Alzheimer's disease in mice

NVP-LGB321, a novel orally bioavailable pan-pim kinase inhibitor

Discovery of a novel IDO pathway inhibitor for cancer-associated immunosuppression

Use of gene therapy as a treatment for congenital blindness

Preclinical development of an anticancer antibody with a unique mechanism of action

New DYRK inhibitors disclosed at AACR meeting

Amgen presents novel potent and orally bioavailable dual kinase inhibitor

Cell>Point reports results from phase IIa cardiovascular study

Development of a new dual EGFR/IGF1R inhibitor

PeptiDream and Ipsen partner on the development of therapeutic peptides

Encouraging findings from phase IIb study of tarafenacin in overactive bladder

H7N9 Replikins vaccine ready for testing

Amorfix Life Sciences reveals latest tumor study findings

Daiichi Sankyo discloses new DGAT1 inhibitors

Novel trypsin inhibitors for renal disorders patented by Astellas Pharma

Scientists at Daiichi Sankyo patent new TAFI inhibitors

Suzhou NeuPharma synthesizes new B-raf and KDR inhibitors

Bayer HealthCare to expand alliance with German Cancer Research Center

Dosing begins in phase II trial of ATL-1103 for the treatment of acromegaly

Pieris and Sanofi expand ongoing discovery and development partnership

FDA grants breakthrough therapy designation to Pfizer's palbociclib

FDA accepts Merck & Co.'s NDA for tablet formulation of antifungal agent

Kowa completes phase III K-115 study

NEI opens study of gevokizumab for noninfectious anterior scleritis

Phase I study of PLX-PAD in PAH cleared to begin

Phase II trial approved for BL-8040

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...